Nevertheless, this study provides proof-of-concept for the further study of these biomarkers as non-invasive imaging tools to report on the downstream cellular consequences of Hsp90 and BRAF-MEK-targeted therapies in melanoma models in vivo with potential significance for patient follow up and management. This evidence concerns the gene BRAF and melanoma.